References
- Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 2010;362(4):329-44
- O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 2011;34:185-204
- Ridge PG, Ebbert MT, Kauwe JS. Genetics of Alzheimer’s disease. Biomed Res Int 2013;2013:254954
- Doraiswamy PM, Krishnan KR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer’s disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002;26(4):705-12
- Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54(12):2269-76
- Gauthier S, Emre M, Farlow MR, et al. Strategies for continued successful treatment of alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003;19(8):707-14
- Small G, Bullock R. Defining optimal treatment with cholinesterase inhibitors in alzheimer’s disease. Alzheimers Dement 2011;7(2):177-84
- Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. The Tacrine Study Group. JAMA 1994;271(13):985-91
- Sadowsky CH, Micca JL, Grossberg GT, et al. Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer’s disease and Parkinson’s disease dementia. Prim Care Companion CNS Disord 2014;16(5):eCollection
- Wentrup A, Oertel WH, Dodel R. Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease. Drug Des Devel Ther 2009;2:245-54
- Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2010;25(4):419-26
- Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in alzheimer disease. Neurology 2007;69(4 Suppl 1):S4-9
- Dhillon S. Rivastigmine transdermal patch: a review of its use in the management of dementia of the alzheimer’s type. Drugs 2011;71(9):1209-31
- Kurz A, Farlow M, Quarg P, et al. Disease stage in alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord 2004;18(3):123-8
- Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2009(2):CD001191
- Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry 2007;22(5):485-91
- Blesa R, Ballard C, Orgogozo JM, et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of alzheimer disease. Neurology 2007;69(4 Suppl 1):S23-8
- Yang LP, Keating GM. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer’s type. CNS Drugs 2007;21(11):957-65
- Farlow MR, Grossberg GT, Meng X, et al. Rivastigmine transdermal patch and capsule in alzheimer’s disease: influence of disease stage on response to therapy. Int J Geriatr Psychiatry 2011;26(12):1236-43
- Alva G, Grossberg GT, Schmitt FA, et al. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Int J Geriatr Psychiatry 2011;26(4):356-63
- Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141(11):1356-64
- Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38
- Feldman HH, Lane R, Study G. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2007;78(10):1056-63
- Grossberg GT, Olin JT, Somogyi M, et al. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease. Int J Clin Pract 2011;65(4):465-71
- Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease--rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22(5):456-67
- Karaman Y, Erdoğan F, Köseoğlu E, Turan T, Ersoy AO. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005;19(1):51-6
- Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003;60(6):843-8